Visus Therapeutics

Visus Therapeutics

  • Founded: 2019
  • Location: Seattle, WA
  • Employee range: 11 - 50
  • Clinical stage: Clin3
  • Therapy area: Presbyopia
  • Drug types: OPH, X_X
  • Lead product: VT-1011 (Brimochol)
  • Product link: https://www.visustx.com/pipeline
  • Funding: $36M A Mar 2021


visustx.com

linkedin.com

job board


Short description:

Presbyopia-correcting eye drops

Drug notes:

VT-1020 Clin0 corneal wound healing; VT-1031 Clin0 high intraocular pressure; VT-1041 Clin0 glaucoma; VT-1051 Clin0 geographic atrophy

Long description:

Visus Therapeutics specializes in the development of novel therapies for ophthalmic diseases. Their scientific efforts are centered around advancing treatments through innovative drug delivery technologies and pharmacology. Visus Therapeutics focuses on optimizing ocular drug formulations to enhance bioavailability and therapeutic efficacy, targeting conditions such as glaucoma and dry eye syndrome. By integrating cutting-edge research in ophthalmic pharmacokinetics and therapeutic innovation, Visus Therapeutics aims to address unmet medical needs and improve patient outcomes in the field of eye care, in an attempt to eliminate preventable blindness. Their multi-targeted therapies are being developed for the front and back of the eye, aiming to preserve visual function and reverse vision loss.

Jobs:


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com